Effect of Sodium−Glucose Co‐Transporter‐2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction
Clinical Cardiology · 2024
DOI: 10.1002/clc.24303 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Cardiology, 2024. Verfasst von Andreasová Taťána und 1 weiteren Autor:innen. Beteiligte Einrichtung: Third Faculty of Medicine, Charles University, Prague, Czech Republic. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Heart Failure, Stroke Volume, Plasma Volume. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institutional Grant MH CZ-DRO (Na Homolce Hospital-NNH), 00023884.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
The increased diuresis after sodium−glucose cotransporter 2 inhibitor (SGLT2i) was associated with a reduction of the estimated plasma volume (ePV) in type 2 diabetic patients. Hypothesis We hypothesized that the early effect of SGLT2i on ePV may be monitored by the change of biomarkers of hemoconcentration. Patients and Methods We analyzed the early‐ and long‐term effect of SGLT2i empagliflozin on the ePV as assessed by biomarkers of hemoconcentration in a nondiabetic patient with heart failure and reduced ejection fraction (HFrEF) and a nondiabetic patient with heart failure and preserved ejection fraction (HFpEF). The ePV was calculated from hemoglobin and hematocrit levels by Duarte formula and ePV change was calculated by Strauss formula.
Results
The ePV change was −22.56% between baseline and 1 month, and −37.60% between baseline and 12 months follow‐up in a patient with HFrEF, and −6.18% and −16.40% in a patient with HFpEF, respectively.
Conclusion
The early effect of SGLT2i on ePV in patients with heart failure may be monitored by biomarkers of hemoconcentration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- Center of Nuclear Medicine, Faculty Hospital Bulovka, Prague, Czech Republic.
- Na Homolce Hospital, Prague, Czech Republic.
Förderung
- Institutional Grant MH CZ-DRO (Na Homolce Hospital-NNH), 00023884
Zitieren
APA
Taťána, A., & Filip, M. (2024). Effect of Sodium−Glucose Co‐Transporter‐2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction. Clinical Cardiology. https://doi.org/10.1002/clc.24303
Vancouver
Taťána A, Filip M. Effect of Sodium−Glucose Co‐Transporter‐2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction. Clinical Cardiology. 2024. doi:10.1002/clc.24303
BibTeX
@article{Tana2024,
author = {Taťána, Andreasová and Filip, Málek},
title = {Effect of Sodium−Glucose Co‐Transporter‐2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction},
journal = {Clinical Cardiology},
year = {2024},
doi = {10.1002/clc.24303}
}
EUVIMED